These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 32393215)
1. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis. Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials. Sethi S; Donohue JF; Ferguson GT; Barnes CN; Crater GD Ther Adv Respir Dis; 2020; 14():1753466620905278. PubMed ID: 32106777 [TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804 [TBL] [Abstract][Full Text] [Related]
4. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD). Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G Respir Res; 2019 Oct; 20(1):241. PubMed ID: 31666076 [TBL] [Abstract][Full Text] [Related]
5. Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very Severe COPD. LeMaster WB; Witenko CJ; Lacy MK; Olmsted AW; Moran EJ; Mahler DA Int J Chron Obstruct Pulmon Dis; 2024; 19():2299-2308. PubMed ID: 39429809 [TBL] [Abstract][Full Text] [Related]
6. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Pudi KK; Barnes CN; Moran EJ; Haumann B; Kerwin E Respir Res; 2017 Nov; 18(1):182. PubMed ID: 29096627 [TBL] [Abstract][Full Text] [Related]
7. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G Respir Med; 2019 Jul; 153():38-43. PubMed ID: 31150963 [TBL] [Abstract][Full Text] [Related]
8. Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease. Donohue JF; Ferguson GT; Ohar JA; Lombardi DA; Schneider RF; Johnson K Respir Med; 2023 Mar; 208():107123. PubMed ID: 36681255 [TBL] [Abstract][Full Text] [Related]
10. Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease. Hvisdas C Am J Health Syst Pharm; 2021 Jun; 78(13):1184-1194. PubMed ID: 33821890 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4. Ohar J; Tosiello R; Goodin T; Sanjar S Int J Chron Obstruct Pulmon Dis; 2019; 14():27-37. PubMed ID: 30587959 [TBL] [Abstract][Full Text] [Related]
12. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833 [TBL] [Abstract][Full Text] [Related]
13. Revefenacin for the treatment of chronic obstructive pulmonary disease. Li F; Yang J Expert Rev Clin Pharmacol; 2019 Apr; 12(4):293-298. PubMed ID: 30803279 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. D'Urzo AD; Singh D; Donohue JF; Kerwin EM; Ribera A; Molins E; Chuecos F; Jarreta D; Gil EG Int J Chron Obstruct Pulmon Dis; 2019; 14():479-491. PubMed ID: 30880938 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial. Vogelmeier CF; Jones PW; Kerwin EM; Boucot IH; Maltais F; Tombs L; Compton C; Lipson DA; Bjermer LH Respir Res; 2021 Oct; 22(1):279. PubMed ID: 34711232 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials. Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Jones PW; Rennard SI; Agusti A; Chanez P; Magnussen H; Fabbri L; Donohue JF; Bateman ED; Gross NJ; Lamarca R; Caracta C; Gil EG Respir Res; 2011 Apr; 12(1):55. PubMed ID: 21518460 [TBL] [Abstract][Full Text] [Related]
18. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607 [TBL] [Abstract][Full Text] [Related]
19. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D; Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625 [TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Donohue JF; Feldman G; Sethi S; Barnes CN; Pendyala S; Bourdet D; Crater G Pulm Pharmacol Ther; 2019 Aug; 57():101808. PubMed ID: 31152911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]